Harmony Biosciences Files 8-K

TL;DR

Harmony Biosciences filed an 8-K on 9/24/25, updating corporate info. Nothing major disclosed yet.

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on September 24, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462, with a business phone number of (484) 539-9800.

Why It Matters

This 8-K filing serves as an official update from Harmony Biosciences Holdings, Inc. to the SEC, providing essential corporate information and disclosures to the public.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not contain information that suggests immediate significant risk.

Key Players & Entities

• Harmony Biosciences Holdings, Inc. (company) — Registrant
• September 24, 2025 (date) — Date of report
• 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462 (location) — Principal executive offices
• (484) 539-9800 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.00001 — ) on which registered Common Stock, $0.00001 par value per share HRMY The Nasdaq

Filing Documents

• hrmy-20250924x8k.htm (8-K) — 48KB
• hrmy-20250924xex99d1.htm (EX-99.1) — 16KB
• hrmy-20250924xex99d1001.jpg (GRAPHIC) — 11KB
• 0001104659-25-092776.txt ( ) — 195KB
• hrmy-20250924.xsd (EX-101.SCH) — 3KB
• hrmy-20250924_lab.xml (EX-101.LAB) — 16KB
• hrmy-20250924_pre.xml (EX-101.PRE) — 10KB
• hrmy-20250924x8k_htm.xml (XML) — 5KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 24, 2025, Harmony Biosciences Holdings, Inc. (the "Company") issued a press release announcing topline data from its phase 3 registrational trial, the RECONNECT study, which did not meet the primary endpoint of improvement in social avoidance primarily due to a higher than expected placebo response rate. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing. Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K constitute "forward-looking statements" within the meaning of the federal securities laws. These statements are based on management's current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward-looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While the Company believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. There are many risks and uncertainties that could cau

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1* Press release issued by the Company, dated September 24, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * This Exhibit is furnished herewith and will not be deemed "filed" for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except to the extent that Harmony Biosciences Holdings, Inc. specifically incorporates it by reference.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARMONY BIOSCIENCES HOLDINGS, INC. Date: September 24, 2025 By: /s/ Christian Ulrich Christian Ulrich SVP and General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR